Life Sciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.

Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Life Sciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"A one-stop-shop for us: its remarkable and successful mix of talent makes it stand out from the rest, and makes our lives much easier."

Chambers UK, 2015

Choose area


    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more


    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more


    The healthcare sector in the UK and internationally continues to experience a period of dynamic change underpinned by significant legal reforms and devolution to the four British nations. As an owner, operator or service provider in this sector, you are facing a highly regulated environment combined with increased public scrutiny. With increasing opportunities for the private provision of healthcare along with an ageing population, but with shrinking public healthcare budgets, operating within the healthcare sector presents both challenges and opportunities.

    Read more


    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    High­lights of our ex­per­i­ence in Life Sci­ences & Health­care...
    Law-Now: Lifes­ci­ences
    Vis­it Law-Now for leg­al know-how and com­ment­ary


    Show only
    Warren Taylor
    Trans­form­ing health and so­cial care
    Pro­gress on the Life Sci­ences Sec­tor Deal 2
    The Of­fice for Life Sci­ences has pub­lished its Feb­ru­ary edi­tion of the Life Sci­ences In­dus­tri­al Strategy & Sec­tor Deal News­let­ter (the “News­let­ter”). The News­let­ter provides an up­date on how the strategy has pro­gressed since phase 2of the Life Sci­ences Sec­tor.
    Vi­tal Signs
    UK Life Sci­ences Re­port
    Valid­ity of pat­ent con­sidered at pre­lim­in­ary in­junc­tion stage
    1. In­tro­duc­tion In a re­cent judg­ment, the High Court con­sidered the valid­ity of a pat­ent at the pre­lim­in­ary in­junc­tion stage, on the basis of a sum­mary judg­ment ap­plic­a­tion brought by Dr Reddy’s Labor­at­or­ies (UK) Lim­ited (“DRL”), a gen­er­ic phar­ma­ceut­ic­al com­pany.
    Carina Healy
    11 November 2018
    Life Sci­ences sec­tor spe­cial­ists
    Changes to Scot­tish pub­lic pro­cure­ment le­gis­la­tion in the event of...
    The Scot­tish Gov­ern­ment has pub­lished a new Pro­cure­ment Policy Note set­ting out pro­posed changes to pub­lic pro­cure­ment le­gis­la­tion in Scot­land in the event the UK leaves the EU without a deal. Most of these changes are tech­nic­al in nature, and they do not fun­da­ment­ally.
    1 May 2017
    CMS, Nabarro and Olswang com­plete largest ever mer­ger...
    Cre­at­ing a new fu­ture-fa­cing firm
    UK gov­ern­ment pub­lishes up­dated pro­cure­ment guid­ance in the event...
    On 14 Janu­ary 2019, the UK gov­ern­ment up­dated its guid­ance in re­la­tion to pub­lic-sec­tor pro­cure­ment in the event of a no-deal Brexit. The guid­ance con­firms that, if the UK leaves the EU without a deal, the pub­lic pro­cure­ment reg­u­la­tions will re­main broadly.
    21 March 2017
    Olswang ad­vises two new VC cli­ents on Series B in­vest­ment...
    Fur­ther guid­ance for life sci­ence com­pan­ies if there is no Brexit...
    Up­dated guid­ance has been is­sued by the UK Medi­cines and Health­care products Reg­u­lat­ory Agency (MHRA) on how the UK would reg­u­late medi­cines, med­ic­al devices and clin­ic­al tri­als in the event that the UK leaves the EU on 29 March 2019 with no with­draw­al ar­range­ments.
    7 March 2017
    Olswang ad­vises IP sup­port ser­vices busi­ness RWS Hold­ings...
    Launch of Life Sci­ences Sec­tor Deal 2
    The In­dus­tri­al Strategy – Life Sci­ences Sec­tor Deal 2 re­port is broken down by themes with each identi­fy­ing what pro­gress has been made by each of the sec­tor and Gov­ern­ment. A sum­mary of these themes and the gen­er­al find­ings are set out be­low:   1.